Humoral and Cellular Immune Responses to SARS-CoV-2 Infection and Vaccination in Autoimmune Disease Patients With B Cell Depletion.


Journal

Arthritis & rheumatology (Hoboken, N.J.)
ISSN: 2326-5205
Titre abrégé: Arthritis Rheumatol
Pays: United States
ID NLM: 101623795

Informations de publication

Date de publication:
01 2022
Historique:
received: 25 04 2021
accepted: 29 06 2021
pubmed: 2 7 2021
medline: 11 1 2022
entrez: 1 7 2021
Statut: ppublish

Résumé

B cell depletion is an established therapeutic principle in a wide range of autoimmune diseases. However, B cells are also critical for inducing protective immunity after infection and vaccination. We undertook this study to assess humoral and cellular immune responses after infection with or vaccination against SARS-CoV-2 in patients with B cell depletion and controls who are B cell-competent. Antibody responses (tested using enzyme-linked immunosorbent assay) and T cell responses (tested using interferon-γ enzyme-linked immunospot assay) against the SARS-CoV-2 spike S1 and nucleocapsid proteins were assessed in a limited number of previously infected (n = 6) and vaccinated (n = 8) autoimmune disease patients with B cell depletion, as well as previously infected (n = 30) and vaccinated (n = 30) healthy controls. As expected, B cell and T cell responses to the nucleocapsid protein were observed only after infection, while respective responses to SARS-CoV-2 spike S1 were found after both infection and vaccination. A SARS-CoV-2 antibody response was observed in all vaccinated controls (30 of 30 [100%]) but in none of the vaccinated patients with B cell depletion (0 of 8). In contrast, after SARS-CoV-2 infection, both the patients with B cell depletion (spike S1, 5 of 6 [83%]; nucleocapsid, 3 of 6 [50%]) and healthy controls (spike S1, 28 of 30 [93%]; nucleocapsid, 28 of 30 [93%]) developed antibodies. T cell responses against the spike S1 and nucleocapsid proteins were found in both infected and vaccinated patients with B cell depletion and in the controls. These data show that B cell depletion completely blocks humoral but not T cell SARS-CoV-2 vaccination response. Furthermore, limited humoral immune responses are found after SARS-CoV-2 infection in patients with B cell depletion.

Identifiants

pubmed: 34196506
doi: 10.1002/art.41914
pmc: PMC8427106
doi:

Substances chimiques

COVID-19 Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

33-37

Subventions

Organisme : Bundesministerium für Wissenschaft und Forschung
Organisme : Deutsche Forschungsgemeinschaft
ID : FOR2886
Organisme : European Research Council
Pays : International

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

© 2021 The Authors. Arthritis & Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.

Références

Blood. 1994 Oct 15;84(8):2457-66
pubmed: 7522629
Arthritis Res Ther. 2020 Feb 22;22(1):36
pubmed: 32087733
Nat Med. 2021 Jun;27(6):981-984
pubmed: 33795870
Arthritis Rheum. 2010 Jun;62(6):1755-62
pubmed: 20191576
Arthritis Rheum. 2013 Feb;65(2):314-24
pubmed: 23124935
N Engl J Med. 2007 Aug 9;357(6):545-52
pubmed: 17687130
N Engl J Med. 2004 Jun 17;350(25):2572-81
pubmed: 15201414
N Engl J Med. 2021 Apr 8;384(14):1372-1374
pubmed: 33691060
N Engl J Med. 2010 Jul 15;363(3):221-32
pubmed: 20647199
Ann Rheum Dis. 2021 Jun;80(6):817-819
pubmed: 33436385
Lancet Rheumatol. 2021 Jun;3(6):e419-e426
pubmed: 33786454
N Engl J Med. 2016 Oct 13;375(15):1487-1489
pubmed: 27732810
N Engl J Med. 2008 Feb 14;358(7):676-88
pubmed: 18272891
Blood. 2013 Sep 12;122(11):1946-53
pubmed: 23851398
Rheumatology (Oxford). 2019 Jun 1;58(6):1075-1085
pubmed: 30649469
Am J Hematol. 2005 Apr;78(4):275-80
pubmed: 15795920
Nat Commun. 2020 Jul 24;11(1):3774
pubmed: 32709909

Auteurs

David Simon (D)

Deutsches Zentrum Immuntherapie, Friedrich-Alexander University Erlangen-Nuremberg, and University Hospital Erlangen, Erlangen, Germany.

Koray Tascilar (K)

Deutsches Zentrum Immuntherapie, Friedrich-Alexander University Erlangen-Nuremberg, and University Hospital Erlangen, Erlangen, Germany.

Katja Schmidt (K)

Deutsches Zentrum Immuntherapie, Friedrich-Alexander University Erlangen-Nuremberg, and University Hospital Erlangen, Erlangen, Germany.

Bernhard Manger (B)

Deutsches Zentrum Immuntherapie, Friedrich-Alexander University Erlangen-Nuremberg, and University Hospital Erlangen, Erlangen, Germany.

Leonie Weckwerth (L)

Deutsches Zentrum Immuntherapie, Friedrich-Alexander University Erlangen-Nuremberg, and University Hospital Erlangen, Erlangen, Germany.

Maria Sokolova (M)

Deutsches Zentrum Immuntherapie, Friedrich-Alexander University Erlangen-Nuremberg, and University Hospital Erlangen, Erlangen, Germany.

Laura Bucci (L)

Deutsches Zentrum Immuntherapie, Friedrich-Alexander University Erlangen-Nuremberg, and University Hospital Erlangen, Erlangen, Germany.

Filippo Fagni (F)

Deutsches Zentrum Immuntherapie, Friedrich-Alexander University Erlangen-Nuremberg, and University Hospital Erlangen, Erlangen, Germany.

Karin Manger (K)

Rheumatology Practice Bamberg, Bamberg, Germany.

Florian Schuch (F)

Rheumatology Practice Erlangen, Erlangen, Germany.

Monika Ronneberger (M)

Rheumatology Practice Erlangen, Erlangen, Germany.

Axel Hueber (A)

Deutsches Zentrum Immuntherapie, Friedrich-Alexander University Erlangen-Nuremberg, and University Hospital Erlangen, Erlangen, Germany.

Ulrike Steffen (U)

Deutsches Zentrum Immuntherapie, Friedrich-Alexander University Erlangen-Nuremberg, and University Hospital Erlangen, Erlangen, Germany.

Dirk Mielenz (D)

Deutsches Zentrum Immuntherapie, Friedrich-Alexander University Erlangen-Nuremberg, and University Hospital Erlangen, Erlangen, Germany.

Martin Herrmann (M)

Deutsches Zentrum Immuntherapie, Friedrich-Alexander University Erlangen-Nuremberg, and University Hospital Erlangen, Erlangen, Germany.

Thomas Harrer (T)

Deutsches Zentrum Immuntherapie, Friedrich-Alexander University Erlangen-Nuremberg, and University Hospital Erlangen, Erlangen, Germany.

Arnd Kleyer (A)

Deutsches Zentrum Immuntherapie, Friedrich-Alexander University Erlangen-Nuremberg, and University Hospital Erlangen, Erlangen, Germany.

Gerhard Krönke (G)

Deutsches Zentrum Immuntherapie, Friedrich-Alexander University Erlangen-Nuremberg, and University Hospital Erlangen, Erlangen, Germany.

Georg Schett (G)

Deutsches Zentrum Immuntherapie, Friedrich-Alexander University Erlangen-Nuremberg, and University Hospital Erlangen, Erlangen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH